全文获取类型
收费全文 | 576817篇 |
免费 | 31408篇 |
国内免费 | 1480篇 |
专业分类
耳鼻咽喉 | 7100篇 |
儿科学 | 18054篇 |
妇产科学 | 13739篇 |
基础医学 | 97866篇 |
口腔科学 | 13330篇 |
临床医学 | 52691篇 |
内科学 | 106936篇 |
皮肤病学 | 12578篇 |
神经病学 | 38215篇 |
特种医学 | 21493篇 |
外国民族医学 | 55篇 |
外科学 | 84562篇 |
综合类 | 9694篇 |
现状与发展 | 3篇 |
一般理论 | 109篇 |
预防医学 | 41005篇 |
眼科学 | 12552篇 |
药学 | 45249篇 |
9篇 | |
中国医学 | 2080篇 |
肿瘤学 | 32385篇 |
出版年
2021年 | 5858篇 |
2019年 | 5202篇 |
2018年 | 7205篇 |
2017年 | 5302篇 |
2016年 | 6113篇 |
2015年 | 6893篇 |
2014年 | 9128篇 |
2013年 | 12883篇 |
2012年 | 18746篇 |
2011年 | 20529篇 |
2010年 | 11826篇 |
2009年 | 10575篇 |
2008年 | 18294篇 |
2007年 | 20012篇 |
2006年 | 19329篇 |
2005年 | 18461篇 |
2004年 | 17853篇 |
2003年 | 16956篇 |
2002年 | 16277篇 |
2001年 | 23590篇 |
2000年 | 24084篇 |
1999年 | 19962篇 |
1998年 | 5649篇 |
1997年 | 4676篇 |
1996年 | 4729篇 |
1995年 | 4380篇 |
1992年 | 14978篇 |
1991年 | 16296篇 |
1990年 | 16412篇 |
1989年 | 16094篇 |
1988年 | 14713篇 |
1987年 | 14568篇 |
1986年 | 13516篇 |
1985年 | 12965篇 |
1984年 | 9620篇 |
1983年 | 8179篇 |
1982年 | 4277篇 |
1979年 | 9124篇 |
1978年 | 6496篇 |
1977年 | 5249篇 |
1976年 | 5586篇 |
1975年 | 6690篇 |
1974年 | 7533篇 |
1973年 | 7266篇 |
1972年 | 6709篇 |
1971年 | 6412篇 |
1970年 | 5968篇 |
1969年 | 5549篇 |
1968年 | 5232篇 |
1967年 | 4693篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
71.
72.
73.
74.
75.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
76.
77.
78.
F. Murina R. Felice S. Di Francesco L. Nelvastellio I. Cetin 《Gynecological endocrinology》2020,36(5):431-435
AbstractThis study is a single-center, retrospective analysis of postmenopausal women presenting with dyspareunia and vulvar pain, aiming to evaluate relative effectiveness of vestibular CO2 laser therapy as a treatment. Three monthly sessions of laser were performed to each patient and thereafter a three-months follow-up was stablished. A total number of 72 patients undergoing vestibular laser treatment were recruited from patient files in the period between 2016 and 2018. Among these, 39 women also received a concomitant treatment with ospemifene (60?mg/day) during the study period. There was a statistically significant reduction of all the symptoms in both groups up to the three month follow-up. Regarding dryness and dyspareunia, the relief tent to be more prominent in the ospemifene?+?laser group at all follow-ups and remained statistically significant at three-month follow-up. Specifically, vestibular dryness was significantly lower in the ospemifene?+?laser group compared with the laser treatment group (?87% vs???34%, respectively), and the vestibular health score started declining faster in the ospemifene?+?laser group. Although, additional research is needed to understand the mechanism of action, our data shows that a combination regimen of laser and ospemifene may improve clinical effectiveness for long-term treatment of symptoms associated with the under-recognized genitourinary syndrome of menopause. 相似文献
79.
目的 初步探讨应用艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎(CHC)患者的疗效。方法 2017年3月~2018年3月仙桃市第一人民医院感染病科收治的CHC患者82例,被随机分为对照组41例和观察组41例,分别给予聚乙二醇干扰素-α联合利巴韦林治疗和艾尔巴韦/格拉瑞韦治疗,两组均连续治疗24周。采用RT- PCR法检测血清 HCV RNA,采用全基因序列测定法行病毒基因分型。比较两组早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)。结果 在治疗结束时,观察组血清丙氨酸氨基转移酶(ALT)水平为(47.9±19.7)U/L,显著低于对照组【(63.5±21.2)U/L,P<0.05】,天冬氨酸氨基转移酶(AST)水平为(55.5±22.3)U/L,显著低于对照组【(81.3±25.8)U/L,P<0.05】;观察组EVR、ETVR和SVR分别为48.8%、63.4%和70.7%,与对照组的41.5%、53.7%和65.8%比,无统计学差异(P>0.05);18例观察组非HCV Ⅰ型感染者EVR、ETVR和SVR分别为88.9%、94.4%和88.9%,显著高于同组23例HCV Ⅰ型感染者(分别为52.2%、60.9%和52.2%, P<0.05),而与对照组15例非HCV Ⅰ型感染者比,无统计学差异(分别为86.7%、93.3%和73.3%, P>0.05);观察组SVR12为87.8%(36/41),显著高于对照组的73.2%(30/41,P<0.05)。结论 应用直接抗病毒(DAA)药物艾尔巴韦/格拉瑞韦治疗CHC患者近期疗效达到,但远期疗效似优于标准治疗方案, 值得临床进一步验证。 相似文献